A friend wrote me recently to describe horrible discomfort from panic attacks, but also significant concerns about the medications his doctor had prescribed. Here’s my answer, in hopes that it may help others out there, too. Dear [friend], Thanks for being willing to reach out. Here are my thoughts. Yes, I know a lot about […]
Lumateperone is a new drug recently approved by the FDA for treatment of schizophrenia. The key clinical trial was just published and includes data on motor side effects of the drug. The sponsor, Intra-Cellular Therapies, Inc., may have data on use in Parkinson disease (PD), but I don’t think any of it is public. So […]
The US FDA approved Epidiolex® (cannabidiol, or CBD) for certain seizure syndromes in June, and today the DEA listed it as a Schedule V controlled substance (the least restrictive). This action will greatly facilitate clinical use and clinical trials of CBD in the U.S. Note that there is little evidence at this point that CBD […]
We were happy to participate in the first-ever study of a dopamine D1 blocking drug in children with TS. The study results were recently published, showing evidence of benefit without substantial side effects. Click here for additional background information, a summary of the results, and a link to the publication. (https://goo.gl/gh5YfM)
Here’s a brief summary of what we know about cannabis and related drugs for treatment of tics.